- Home
- WRN vs DSGN Comparison
WRN vs DSGN Comparison
Compare WRN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRN
- DSGN
- Stock Information
- Founded
- WRN 2006
- DSGN 2017
- Country
- WRN Canada
- DSGN United States
- Employees
- WRN N/A
- DSGN N/A
- Industry
- WRN Metal Mining
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- WRN Basic Materials
- DSGN Health Care
- Exchange
- WRN Nasdaq
- DSGN Nasdaq
- Market Cap
- WRN 246.0M
- DSGN 208.9M
- IPO Year
- WRN N/A
- DSGN 2021
- Fundamental
- Price
- WRN $1.33
- DSGN $4.02
- Analyst Decision
- WRN Strong Buy
- DSGN Hold
- Analyst Count
- WRN 1
- DSGN 1
- Target Price
- WRN $4.00
- DSGN $4.00
- AVG Volume (30 Days)
- WRN 377.8K
- DSGN 97.8K
- Earning Date
- WRN 08-08-2025
- DSGN 08-04-2025
- Dividend Yield
- WRN N/A
- DSGN N/A
- EPS Growth
- WRN N/A
- DSGN N/A
- EPS
- WRN N/A
- DSGN N/A
- Revenue
- WRN N/A
- DSGN N/A
- Revenue This Year
- WRN N/A
- DSGN N/A
- Revenue Next Year
- WRN N/A
- DSGN N/A
- P/E Ratio
- WRN N/A
- DSGN N/A
- Revenue Growth
- WRN N/A
- DSGN N/A
- 52 Week Low
- WRN $0.90
- DSGN $2.60
- 52 Week High
- WRN $1.42
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- WRN 56.87
- DSGN 52.03
- Support Level
- WRN $1.21
- DSGN $3.95
- Resistance Level
- WRN $1.37
- DSGN $4.44
- Average True Range (ATR)
- WRN 0.06
- DSGN 0.25
- MACD
- WRN 0.00
- DSGN 0.02
- Stochastic Oscillator
- WRN 72.22
- DSGN 54.35
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.